Dec 23, 2025 • TipRanks
NEUTRAL
Krystal Biotech announces resignation of longtime board member
Krystal Biotech announced the resignation of board member Kirti Ganorkar, effective December 31, 2025. His departure is attributed to new responsibilities at Sun Pharma and not disagreements with Krystal Biotech's operations. The company thanked him for his contributions since its public listing in 2017.
Dec 23, 2025 • TradingView — Track All Markets
NEUTRAL
Krystal Biotech Announces Board Resignation
Krystal Biotech, Inc. announced that Kirti Ganorkar will resign from its Board of Directors effective December 31, 2025. This resignation is due to Mr. Ganorkar’s increased responsibilities following a promotion at Sun Pharma. He had served on the board since September 2017.
Dec 23, 2025 • MarketBeat
BULLISH
Krystal Biotech, Inc. $KRYS Shares Purchased by Voya Investment Management LLC
Voya Investment Management LLC significantly increased its stake in Krystal Biotech, Inc. (NASDAQ:KRYS) during Q3, now owning 93,908 shares valued at $16.58 million. The company's stock has seen positive analyst sentiment, with a consensus "Moderate Buy" rating and a price target of $228.14. Krystal Biotech recently reported strong earnings, beating EPS and revenue estimates, and its shares are trading near a 12-month high with a market cap of $7.24 billion.
Dec 23, 2025 • Investing.com Nigeria
BULLISH
Krystal Biotech stock hits all-time high at 248.82 USD By Investing.com
Krystal Biotech (KRYS) stock reached an all-time high of $248.82, showing an 81.79% return over the past six months and a 53.88% increase over the last year. The company's financial health is rated "EXCELLENT" by InvestingPro with a 94.26% gross profit margin and 54.51% revenue growth. This milestone follows a notable earnings beat for Q3 2025, where EPS of $2.66 significantly surpassed the forecast of $1.09.
Dec 23, 2025 • Investing.com
BULLISH
Krystal Biotech stock hits all-time high at 248.82 USD
Krystal Biotech Inc. (KRYS) stock reached an all-time high of $248.82, driven by a 53.88% increase over the past year and an 81.79% return in the last six months with low volatility. The company's financial health is rated as "EXCELLENT" by InvestingPro, boasting a 94.26% gross profit margin and 54.51% revenue growth. This performance is further supported by a significant Q3 2025 earnings beat, with EPS of $2.66 against a forecasted $1.09.
Dec 22, 2025 • Investing.com India
BULLISH
Krystal Biotech stock hits all-time high at 248.82 USD
Krystal Biotech Inc. stock reached an all-time high of $248.82, driven by a 53.88% increase over the past year and an 81.79% return in six months with low volatility. The company showcases strong financial health with a 94.26% gross profit margin and 54.51% revenue growth, earning an "EXCELLENT" rating from InvestingPro. This surge follows a significant Q3 2025 earnings beat, reinforcing investor confidence despite minor pre-market fluctuations.